RxDoctor Payments Data

William Threlkeld, MD

Family Medicine · Williamstown, KYNPI 1205893112

Payments from drug & device makers

$7,857in general payments, 2019–2025

Across 500 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • GSK$658
  • AstraZeneca$419
  • Pfizer$358
  • Novartis$350
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,832100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,857 in reported general payments places this provider in the 90th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$59,518
Medicare patients
241
Services billed
2,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$84,027
MounjaroTirzepatide57$83,162
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$80,155
FarxigaDapagliflozin Propanediol77$77,284
OzempicSemaglutide51$66,392
JardianceEmpagliflozin56$65,173
Tresiba Flextouch U-200Insulin Degludec18$33,109
XareltoRivaroxaban26$26,842
JanuviaSitagliptin Phosphate29$24,577
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$18,541
Breo ElliptaFluticasone/Vilanterol33$16,639
VascepaIcosapent Ethyl30$16,472
MyrbetriqMirabegron29$16,183
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$14,021
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$10,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$658$106,923122 claims
AstraZenecaFarxiga, Breztri Aerosphere, Airsupra$419$102,688113 claims
PfizerEliquis, Paxlovid$358$85,45699 claims
Lilly USA, LLCMounjaro$347$83,16257 claims
Boehringer IngelheimJardiance, Pradaxa$116$68,70175 claims
Novo NordiskOzempic$1,173$66,39251 claims
Johnson & JohnsonXarelto$134$26,84226 claims
MerckJanuvia$38$24,57729 claims
Astellas Pharma US IncMyrbetriq$132$16,18329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Williamstown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →